Chronoscale Holdings Corp current report, 09 August 2016

Business Context and Reporting Period

This Form 8-K was filed by Ekso Bionics Holdings, Inc. on August 9, 2016. The report details the pricing of an underwritten public offering and the commencement of trading on The NASDAQ Capital Market under the symbol "EKSO".

Key Financial Metrics

  • Offering Size: 3,750,000 shares of common stock.
  • Offering Price: $4.00 per share.
  • Net Proceeds: $13.7 million (after deducting underwriting discounts and offering expenses).
  • Par Value: $0.001 per share.

The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity metrics.

Material Changes

The primary material change is the transition to a publicly traded entity on The NASDAQ Capital Market effective August 9, 2016, resulting in an immediate increase in cash liquidity of $13.7 million from the share offering.

Guidance, Outlook, and Risks

Management commentary is limited to the announcement of the offering pricing and listing approval. The filing does not contain specific forward-looking guidance, risk factors, contingencies, or unusual items beyond the standard disclosure of the capital raise.

Investor Verification Checklist

  • Verify the final listing status and trading volume of "EKSO" on The NASDAQ Capital Market.
  • Confirm the exact amount of underwriting discounts and expenses deducted to reach the $13.7 million net proceeds.
  • Review the attached press release (Exhibit 99.1) for details on the intended use of proceeds.
  • Check for any lock-up agreements or insider selling restrictions associated with the offering.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.